Cardiology

The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’…

In our latest issue of EMJ Cardiology you can explore a wide range of exclusive interviews with field experts, insightful peer-reviewed…

The AZALEA-TIMI 71 trial is the first study to provide definitive evidence that factor XI inhibition substantially reduces bleeding…

Explore a unique selection of peer-reviewed articles, exclusive interviews with leading experts, and a comprehensive review of the ESC Congress…

This informative podcast spotlights the current treatment landscape of hypertrophic cardiomyopathy (HCM), detailing typical diagnosis and outlining the use of echocardiography for obstructive HCM. Featured on this episode is Fabian Knebel, Senior Consultant for the Department of Cardiology and Angiology, Charité–Universitätsmedizin, Berlin, and Head of the Cardiology Department, Sana Klinikum Lichtenberg, Berlin, Germany.

Amyloid light-chain (AL) amyloidosis is a rare systemic disease caused by plasma cell dyscrasia. These plasma cells produce excess Ig light chains, which can misfold, aggregate, and deposit in tissues, resulting in toxicity and organ dysfunction. The heart is among the most commonly affected organs and cardiac involvement is associated with significantly worse outcomes.

Obstructive HCM is a condition in which the heart has thickened walls that are not caused by blockage of the heart valves or by very high blood pressure. For the majority of patients, the cause of their disease has a genetic basis and is hereditary.

Despite the increasing prevalence of raised blood pressure and hypertension, many patients remain undiagnosed due to a lack of symptoms. Hypertension presents considerable risks for patients with cardiovascular diseases, and currently has limited effective interventions.